Enhanced Preservative-Free Intranasal Composition for Pain Relief

An improved preservative-free intranasal composition for treating various pain conditions, featuring optimized concentrations, pH ranges, and spray device configurations to enhance efficacy and user experience.

The original patent disclosed a preservative-free intranasal composition for pain relief, but it had limitations in terms of dosage, pH, and spray device design. The new inventive concept addresses these limitations by introducing metered dose spray devices, optimized pH ranges, and improved droplet size distributions, providing a more efficient and effective treatment option.

The new inventive concept comprises a preservative-free intranasal composition containing a locally active sodium channel blocker, such as lidocaine, in a concentration range of 2% to 12%. The composition is designed to be administered via a metered dose spray device, which provides a precise volume of 0.01 ml to 0.2 ml per spray. The pH range of the composition is optimized to be between 4.5 and 6.5, ensuring maximum efficacy and comfort for the user. The spray device is designed to produce a droplet size distribution of 10 microns to 200 microns, allowing for efficient absorption and minimizing irritation. The composition can be used to treat various pain conditions, including tri-geminal neuralgia, facial neuropathic pain, migraine pain, and cluster headache pain.

The new inventive concept introduces a novel combination of optimized concentration, pH range, and spray device configuration, which provides a significant improvement over the original patent. The use of metered dose spray devices and optimized droplet size distributions are key innovations that enhance the efficacy and user experience of the preservative-free intranasal composition.

Alternative embodiments of the inventive concept could include different concentrations of the locally active sodium channel blocker, varying pH ranges, and different spray device designs. For example, a bi-dose spray device could be used for cluster headache pain, or a unit dose spray device could be used for facial neuropathic pain. Additionally, the composition could be modified to include other locally active sodium channel blockers or other pain-relieving agents.

The enhanced preservative-free intranasal composition has significant commercial potential in the pain relief market, particularly in the treatment of tri-geminal neuralgia, facial neuropathic pain, migraine pain, and cluster headache pain. The optimized composition and spray device design could provide a competitive advantage in the market, and the potential for partnerships with pharmaceutical companies or licensing agreements could be explored.